Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer
- Authors:
- Published online on: December 1, 2014 https://doi.org/10.3892/mco.2014.469
- Pages: 303-307
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
This study was conducted with the aim to investigate the feasibility of intermittent treatment with docetaxel chemotherapy for castration‑resistant prostate cancer (CRPC). A total of 51 men with CRPC received docetaxel at 75 mg̸m2 every 3 weeks combined with oral dexamethasone 1.0‑2.0 mg̸day between 2008 and 2013. The prostate‑specific antigen (PSA) level was monitored every 3 weeks. Chemotherapy was suspended when the serum PSA level decreased to <4 ng̸ml, with a reduction rate of >50% from the baseline. Treatment was resumed when serum PSA increased to >2 ng/ml, with an increase rate of >50% from the nadir. Of the 51 cases, 27 (52.9%) qualified for intermittent treatment; 17 patients received two courses of docetaxel chemotherapy and 10 received three courses. The median off‑treatment interval was 266 days for the first drug holiday, 129.5 days for the second and 146.5 days for the third. The multivariate analysis indicated low baseline PSA (
Related Articles
March-2015
Volume 3 Issue 2
Print ISSN: 2049-9450
Online ISSN:2049-9469
